Gobia Enterprises invests in Bioelectrix: a complete team to bring bioelectronic wound healing to patients
Bioelectrix welcomes Gobia Enterprises as a new owner, and Jan Erik Smith and Tina Kjellén to its board. With them comes the wound care experience needed to take a promising technology to the next stage.
We are proud to announce that Gobia Enterprises has invested in Bioelectrix. As part of the investment, Jan Erik Smith of Gobia joins our board, together with wound care clinical expert Tina Kjellén.
For us, this is about more than funding. It means we now have a complete team, with the experience and breadth of knowledge to take our technology from the lab to the patients who need it.

The investment
Gobia Enterprises builds on the Smith family’s experience of developing ABIGO Medical into an international wound care business. They know what it takes to bring wound care products to market and grow internationally, which is exactly what a young company like ours needs at this stage. Beyond capital, Gobia will contribute strategic input on industry partnerships, intellectual property and future financing.
“Having previously been involved in building an international wound care business through ABIGO Medical, we have seen firsthand the challenges of treating difficult wounds. What particularly attracted us to Bioelectrix is its ambition to go beyond managing wounds and actively influence the biological healing process itself. We look forward to contributing our experience as the company advances towards clinical application.” – Jan Erik Smith, Gobia Enterprises
Our board and team
We are first-time founders. We know we have created an amazing technology, but we also know that taking a medical device all the way to patients takes experience we don’t yet have ourselves. That is why, from day one, we have focused on building the right team around us.
Bioelectrix is led by co-founders Caroline Johansen (CEO) and José Leal (CTO). Co-founder Maria Asplund’s research at Chalmers laid the scientific foundation for the company. Our board is chaired by Jan Hörling and now includes Tina Kjellén, former clinical lead at woundEL, bringing very important experience to our board. Mattias Munnich of Chalmers Ventures and Henrik Claesson also support us at board level. And now Jan Erik Smith adds first-hand experience of growing an international wound care business.
Together, we cover the whole journey from research to market: bioelectronics, engineering, regulatory and quality, clinical wound care, finance and commercial experience from the wound care industry.
“With Jan Erik and Tina joining our board, we now have a complete team with the breadth of expertise to take Bioelectrix all the way to patients.” – Caroline Johansen, CEO and co-founder, Bioelectrix
Where this takes us
With the investment and a strengthened board in place, we are ready for the next stage. In 2027 we will build stronger evidence of the treatment effect on human skin, complete our stimulation system and secure European patent protection. We will also deepen our dialogue with established wound care companies, where Gobia’s industry experience will make a real difference.
These milestones lay the foundation for our next financing round, planned for 2027, and for our first clinical study in patients, where Tina’s clinical experience will be central. Our long-term goal is CE marking around 2030, making bioelectronic wound healing available to patients across Europe.
About Bioelectrix
Bioelectrix Sweden AB is a Gothenburg-based medtech company developing a wearable electrode that restores the body’s natural electrical healing signal, helping chronic wounds close faster. The patent-pending technology comes from research at Chalmers University of Technology, and in lab studies on human skin cells, wounds closed up to three times faster. Bioelectrix was founded in 2025 and is based at CoAx, Sahlgrenska Science Park.
Want to know more, or explore working with us? Contact Caroline Johansen.